Canada Approves BeiGene BRUKINSA for Mantle Cell Lymphoma

Canada Approves BeiGene BRUKINSA for Mantle Cell Lymphoma

Health Canada has granted BeiGene approval for BRUKINSA (Zanubrutinib) to treat mantle cell lymphoma (MCL) in adults who have already received at least one other prior treatment. As global, science-driven biotechnology company, BeiGene focuses on improving treatment...